Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12
weeks in patients with non-alcoholic steatohepatitis. J Hepatol 2021 Feb 10. pii: S0168-8278(21)00099.
PMID: 33581174